MedTrace Logo

Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease

NCT02080364 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 880

Last updated 2021-05-07

Study results available
· View outcomes & findings →

Summary

This is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimer's disease. Patients will receive either azeliragon or placebo with a patient's participation lasting approximately 18 months.

Conditions

Interventions

DRUG

Azeliragon

Azeliragon 5mg administered orally, once daily for 18 months

DRUG

Placebo

Placebo administered orally, once daily for 18 months

Sponsors & Collaborators

  • vTv Therapeutics

    lead INDUSTRY

Principal Investigators

  • Aaron H Burstein, PharmD · vTv Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2018-06-01
Completion
2018-06-01
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • Ireland
  • New Zealand
  • South Africa
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02080364 on ClinicalTrials.gov